Capitalmind
Capitalmind
Actionable insights on equities, fixed-income, macros and personal finance Start 14-Days Free Trial
Actionable investing insights Get Free Trial
Stocks

Lupin Profits Grow by 56%, gGlumetza Exclusivity Expires : Results Analysis

Lupin-Logo.png

Lupin had a good numbers in terms of sales i.e  41% growth QoQ. The net profits saw a growth of 56% QoQ.

Key Takeaways:Lupin Logo

  • Operating Margin went up from 22.92% to 24.89%. Which is a marginal increase, but an increase nevertheless.
  • Expenditure on R&D has increased substantially by 59.52% QoQ and currently stands at 499.4 Crs.
  • Finance Cost has gone up substantially, up by 4.55 times. Increase in finance costs was mainly due to acquisition of Gavis, most of which was funded by debt.
  • Lupin has paid 23.65% of PBT as taxes  for the reported period compared to 28.50% for the same quarter previous year.

Lupin Q1FY17 Results

  • Lupin’s 180 days exclusivity of generic drug of Glumetza expired on Aug 2,2016.
  • Lupin has received an Establishment inspection Report for its Goa facility, regarding an inspection done in July Last year.
  •  Inspection done in March for the Goa Facility, the EIR is till pending.

The share price tumbled down by 5.52% to close at Rs 1599.90. This has been explained in online channels as not meeting expectations. But you know how markets are!
Lupin Q1FY17 Share Price Movement
You might also like:

divider

Disclaimer

Nothing in this newsletter is financial advice and should not be construed as such. Please do not take trading decisions based solely on the matter above; if you do, it is entirely at your own risk without any liability to Capital Mind. This is educational or informational matter only, and is provided as an opinion.
Disclosure: The authors at Capital Mind have positions in the market and some of them may support or contradict the material given above, or may involve a direction derived from independent analysis.